The randomized phase II AVANOVA trial compared niraparib plus the Vascular Endothelial Growth Factor-A (VEGF-A) inhibitor bevacizumab to niraparib alone in platinum-sensitive recurrent ovarian cancer patients [88]. Here, VEGFA is linked to ovarian carcinoma.